EVE.ASX: Fast-Acting Health Treatments Set to Disrupt ED and Period Pain
Small Caps
Host
Now Playing
Intro and Eve Health Group overview
Featured Companies
Analysis: Eve Health Group (EVE.ASX) — two new fast-acting health products powered by nano emulsion technology.
In this video, we unpack the business, technology and timeline behind Eve Health Group's march into women's and men's health with Dispro Pastels and Libo. We'll cover what the products are, how the nano emulsion technology accelerates onset to around 15 minutes, market size (women's health and ED), regulatory path (TGA registration), and the company's international growth plan. We'll also introduce incoming CEO Damian Wood and the new scientific advisory board member Dr Fiona Cousins, and lay out near-term milestones for the next 12 months. If you're an investor or follower of ASX small-caps, this video will bring you up to speed on Eve Health Group's strategy and potential catalysts.
If you found this analysis helpful, subscribe to stay updated on Eve Health Group's progress and share your thoughts in the comments.
Related Articles
5
EVE Health Group Appoints First Member of New Scientific Advisory Board
EVE Health Group (ASX: EVE) has appointed senior research scientist Dr Fiona Cousins as the inaugural member of its new scientific advisory board. Dr Cousins has more than a decade of experience in reproductive biology and women’s health research, and currently works at The Ritchie Centre within the Hudson Institute of Medical Research in Victoria, […]
EVE Health Group Advances ED Treatment with First Order for Libbo
EVE Health Group (ASX: EVE) has submitted its first commercial purchase order for Libbo, the company’s proprietary oral dissolving film treatment for erectile dysfunction (ED). One of the company’s GMP-certified pharmaceutical partners received the order, and EVE expects first shipments to Australia in the December quarter. EVE needs to make no further regulatory steps, paving […]
EVE Health and TeleDocs to launch online prescription service for erectile dysfunction and period pain treatments
EVE Health Group’s (ASX: EVE) wholly-owned subsidiary Nextract has signed an agreement with TeleDocs Clinic & Consulting for the online prescription and promotion of its lead pharmaceutical products for erectile dysfunction (ED) and dysmenorrhoea (period pain). The two-year agreement sees TeleDocs become the first online clinic and telehealth provider authorised to prescribe Libbo+ oral soluble […]
EVE Health Group completes takeover of Nextract, strengthens executive team
EVE Health Group (ASX: EVE) has completed its strategic acquisition of biotech company Nextract in a major product growth move by the company. The successful purchase adds significant development upside in the $8.1 billion erectile dysfunction (ED) market, with Nextract’s lead product targeting therapeutic onset within 15 minutes of dosage. Nextract is developing proprietary oral […]
EVE Health Group begins stability testing of oral treatments for ED and period pain
EVE Health Group (ASX: EVE) has commenced stability testing of its leading oral formulation products for treating erectile dysfunction (ED) and dysmenorrhoea (period pain). Stability testing is mandatory under pharmaceutical product research guidelines to ensure new drugs maintain quality, safety and efficacy under various environmental conditions across their designated shelf life. Testing examines physical, chemical […]
Never Miss an Episode
Subscribe to get notified about new episodes and exclusive content
Small Caps
Host & Market Analyst